Skip to content

Effective exercise for people with Multiple Sclerosis

Effective exercise for people with Multiple Sclerosis: a single-blind randomised non-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN89009719
Enrollment
60
Registered
2007-11-15
Start date
2008-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Nervous System Diseases Multiple sclerosis

Interventions

Three exercise groups will perform the same amount of exercise within sessions delivered in different ways: 1. Shorter and hard (anaerobic) 2. Longer and easy (aerobic) 3. A combination of both aerob

Sponsors

Oxford Brookes University (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults (over 18 years, either sex) with Multiple Sclerosis (MS) 2. Able to sit and pedal on a cycle ergometer and complete 60 seconds unloaded exercise 3. Ambulatory with/without a walking aid

Exclusion criteria

Exclusion criteria: 1. Serious medical condition or complication that would preclude safe exercise 2. Sudden change/relapse in MS 3. Cognitively unable to consent

Design outcomes

Primary

MeasureTime frame
Two-minute walk distance, measured at baseline, week 6 (half-way intervention), week 12 (end intervention) and week 24 (follow up).

Secondary

MeasureTime frame
1. Questionnaires: 1.1. Barthel Index of independence in activities of daily living 1.2. Fatigue Severity Scale (FSS): self reported fatigue levels 1.3. Physical Activity Questionnaire in the Elderly (PASE): self reported activity levels in home, work and social environments 1.4. General Health Status questionnaire - 36-item Short Form health survey (SF-36): Patient-completed health status measure 1.5. Short Orientation Memory Concentration scale (SOMC): measure of orientation, memory and concentration 1.6. Subjective vitality ?individual difference? scale: self reported energy levels scale 1.7. Self efficacy scale: confidence to take complete exercise scale 2. Anthropodmetry: weight (kg), height (m) and leg-length (cm) (anterior superior iliac spine to med. Malleolus) 3. Muscle performance: extensor leg power - measurement of leg extension power in sitting 4. Mobility: 4.1. Step count during 8 days measured with a Step Activity Monitor (watch sized device worn on ankle)* 4.2. Timed up and go test (sit to stand from chair and walk 5 metres) 4.3. During 2 minute walk test (walking characteristics (step time and length) recorded with a small accelerometer worn on back) 5. Hydration status: urine analysis 6. Blood test: of neurotrophic factors (proteins associated with brain function) and immune markers* 7. Fitness test: 7.1. Heart Rate (HR): heart rate monitor 7.2. Blood pressure: arm cuff measure 7.3. Rating of perception of effort and symptoms (Breathing and Leg effort): self report 7.4. Enjoyment S-bipolar scale: self report 7.5. Rate of oxygen consumption (metabolism): measurement of expired air 7.6. Muscle response to exercise (blood lactate levels): finger prick (capillary) blood samples 8. Qualative analysis of focus group meetings and interviews Secondary outcome measures will be measured at baseline, week 6 (half-way intervention), week 12 (end intervention) and week 24 (follow up). *Neurotrophic factors, immune markers and step activity will only be m

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026